First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation ...